Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03784300 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of PTI-125 in Healthy Volunteers
A Phase 1 study of Alzheimer Disease and Alzheimer Disease, Early Onset, sponsored by Pain Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03784300 is a Phase 1 study of Alzheimer Disease and Alzheimer Disease, Early Onset that has completed, run by Pain Therapeutics. The registered enrollment target is 24 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03784300, a Phase 1 study of Alzheimer Disease and Alzheimer Disease, Early Onset, has completed, sponsored by Pain Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers
Conditions Studied
Interventions
- DRUG 50 mg PTI-125
- DRUG 100 mg PTI-125
- DRUG 200 mg PTI-125
Study Locations (1)
Texas
- Worldwide Clinical Trials - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-08-18 |
| Est. Completion | 2018-03-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03784300
The ClinicalTrials.gov registry entry for NCT03784300 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The listed sponsor is Pain Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 3 interventions - of which 50 mg PTI-125 is the first listed.
NCT03784300 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03784300 about?
NCT03784300 is a clinical study titled "A Safety Study of PTI-125 in Healthy Volunteers". A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers
What is the current status of trial NCT03784300?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2017-08-18. Estimated completion is 2018-03-27.
What conditions does trial NCT03784300 study?
This clinical trial studies the following conditions: Alzheimer Disease, Alzheimer Disease, Early Onset.
What interventions are being tested in trial NCT03784300?
The interventions under investigation include: 50 mg PTI-125 (DRUG), 100 mg PTI-125 (DRUG), 200 mg PTI-125 (DRUG).
Who is sponsoring clinical trial NCT03784300?
This trial is sponsored by Pain Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03784300 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
-
Nicotinic Acid for the Treatment of Alzheimer's Disease
RECRUITING · Phase 1
-
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
RECRUITING · Phase 1
-
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
RECRUITING · Phase 1
-
Assess Fibrin in Brains With AD/ADRD
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.